Objective To summarize current research status of sperm protein 17 (SP17) in breast cancer. Method Bysearching PubMed, Web of Science, CNKI, and Wanfang databases, the studies about expression and function of SP17 in the breast cancer were summarized. Results SP17 only expressed in the breast cancer tissue but not in the normal breast tissue. The result of the study showed that SP17 was only detected in the metastatic stage of tumor cells. The preclinical trails found that the breast cancer cells with SP17 positive expression could be killed by the specific T lymphocyte. Conclusions SP17 might be a potential target of immunotherapy of breast cancer, it might promote metastasis of cancer. More studies are needed to further explore its function in tumor development, thus accelerate its application in clinical practice.
目的:探讨IVF-ET周期中,对常规IVF完全受精失败的卵子补行卵胞浆内单精子注射精子(Rescue ICSI)的临床应用价值。方法:在常规IVF后18～22 h,对体外受精完全失败的12个周期、85个未受精MⅡ期卵行补行ICSI。以同时期进行ICSI的34个周期、226个MⅡ期卵为对照,比较ICSI结局。结果:补救ICSI组与对照组比较,基础内分泌指标,HCG 日平均血清雌二醇和孕激素水平、子宫内膜厚度,获MⅡ期卵个数以及平均移植胚胎个数,无显著性差异。补救ICSI组受精率和卵裂率分别为78.82％、91.04％,与对照组(受精率为80.09%,卵裂率为95.58%)比较,差异无统计学意义。取卵后第3天,补救ICSI组卵裂球数≥5的优质胚胎比例占13.11％,低于对照ICSI组(73.99％),差异有显著性 (Plt;0.05)。对照ICSI组妊娠率为38.24％,补救ICSI组无一例妊娠。结论:补行ICSI虽然可使常规IVF中未受精卵受精并获得胚胎,但是所得胚胎的发育潜能差,妊娠率极低,临床应用价值有限。
目的：探讨雌激素影响人精子顶体反应的可能机制。方法：应用异硫氰酸荧光素标记豌豆凝集素荧光染色法（FITC-PSA）分析精子顶体反应（AR）、以分光光度比色法测定顶体酶（ACE）活性。结果：17β-雌二醇（17β-E2）可促进精子发生AR，并增强精子顶体酶的活性；去除培养液中的Ca2+后，17β-E2不能诱导精子发生AR；PKC抑制剂能明显降低17β-E2所诱导的AR；E2-BSA亦能够促进精子发生AR，其作用与17β-E2无显著差异。结论：雌激素对人精子顶体反应有一定的促进作用，增强精子顶体酶活性可能是其作用途径之一，此过程涉及了胞外Ca2+、PKC及精子膜上的ER或雌激素结合位点的参与。
ObjectiveTo systematically review the efficacy and safety of CoQ10 for idiopathic oligoasthenoteratozoospermia (iOAT). MethodsWe searched databases including PubMed, EMbase, MEDLINE, The Cochrane Library, CBM, CNKI, VIP and WanFang Data from inception to May 31th 2016 for randomized controlled trials (RCTs) on CoQ10 in the treatment of iOAT. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed using RevMan 5.3 software. ResultsSeven RCTs involving 803 patients were included. The results of meta-analysis showed, compared with the control group, the CoQ10 group could significantly increase sperm concentration (MD=3.37, 95%CI 0.68 to 6.05, P=0.01), the number of A grade spermatozoa (MD=5.06, 95%CI 3.84 to 6.28, P < 0.000 01), the number of A+B grade spermatozoa (MD=7.72, 95%CI 4.19 to 11.26, P < 0.000 1), the rate of morphologically normal sperm (MD=1.89, 95%CI 0.63 to 3.16, P=0.003) and sperm coenzyme Q10 level (MD=40.02, 95%CI 24.73 to 55.31, P < 0.000 01), while not improve the levels of serum sex hormone (FSH: MD=–3.48, 95%CI –5.17 to –1.79, P < 0.000 1; LH: MD=–3.23, 95%CI –7.55 to 1.08, P=0.14; T: MD=0.45, 95%CI –3.31 to 4.20, P=0.82). No significant difference in adverse event was noted between two groups. ConclusionThe evidence suggests that CoQ10 as empiric medical therapy for iOAT with low non-serious adverse event associated, may improve sperm concentration and percent sperm motility. However, the strength of evidence is low due to high risk of bias of the included studies. More rigorous studies are needed to verify the above conclusion.